PCSA
NASDAQProcessa Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.14+0.12 (+5.94%)
02:00 PM03:15 PM
News · 26 weeks47-72%
2025-12-212026-06-14
Mix3990d
- Insider35(90%)
- SEC Filings4(10%)
Latest news
25 items- INSIDERPres. Research & Development Young David bought $4,590 worth of shares (1,786 units at $2.57), increasing direct ownership by 12% to 17,131 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Financial Officer Skibsted Russell bought $5,890 worth of shares (2,292 units at $2.57), increasing direct ownership by 27% to 10,758 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Executive Officer Ng George K bought $5,472 worth of shares (2,129 units at $2.57), increasing direct ownership by 27% to 9,970 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Business - Strategy Off Lin Patrick bought $4,066 worth of shares (1,582 units at $2.57), increasing direct ownership by 21% to 9,176 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Administrative Officer Guy Wendy bought $4,701 worth of shares (1,829 units at $2.57), increasing direct ownership by 23% to 9,840 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Executive Officer Ng George K bought $5,474 worth of shares (1,843 units at $2.97), increasing direct ownership by 31% to 7,841 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERPres. Research & Development Young David bought $4,589 worth of shares (1,545 units at $2.97), increasing direct ownership by 11% to 15,345 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Business - Strategy Off Lin Patrick bought $4,066 worth of shares (1,369 units at $2.97), increasing direct ownership by 22% to 7,594 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Administrative Officer Guy Wendy bought $4,702 worth of shares (1,583 units at $2.97), increasing direct ownership by 25% to 8,011 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Financial Officer Skibsted Russell bought $5,892 worth of shares (1,984 units at $2.97), increasing direct ownership by 31% to 8,466 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERAmendment: Chief Executive Officer Ng George K bought $5,474 worth of shares (1,843 units at $2.97), increasing direct ownership by 86% to 3,979 units (SEC Form 4)4/A - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERAmendment: Chief Development Officer Bigora Sian bought $5,341 worth of shares (1,971 units at $2.71), increasing direct ownership by 36% to 7,481 units (SEC Form 4)4/A - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- SECSEC Form 10-Q filed by Processa Pharmaceuticals Inc.10-Q - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- INSIDERPres. Research & Development Young David bought $4,589 worth of shares (1,706 units at $2.69), increasing direct ownership by 14% to 13,813 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Financial Officer Skibsted Russell bought $5,891 worth of shares (2,190 units at $2.69), increasing direct ownership by 51% to 6,498 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Executive Officer Ng George K bought $5,471 worth of shares (2,034 units at $2.69), increasing direct ownership by 51% to 6,013 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Business - Strategy Off Lin Patrick bought $4,065 worth of shares (1,511 units at $2.69), increasing direct ownership by 32% to 6,236 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Administrative Officer Guy Wendy bought $4,702 worth of shares (1,748 units at $2.69), increasing direct ownership by 37% to 6,441 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Development Officer Bigora Sian bought $5,342 worth of shares (1,986 units at $2.69), increasing direct ownership by 36% to 7,496 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- SECAmendment: SEC Form 10-K/A filed by Processa Pharmaceuticals Inc.10-K/A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- SECProcessa Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- INSIDERAmendment: Chief Executive Officer Ng George K bought $5,415 worth of shares (2,136 units at $2.54) (SEC Form 4)4/A - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERAmendment: Chief Executive Officer Ng George K bought $5,474 worth of shares (1,843 units at $2.97), increasing direct ownership by 86% to 3,979 units (SEC Form 4)4/A - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Young David4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Ng George K4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
PCSA FAQ
6 questionsWhat does Processa Pharmaceuticals Inc. do?
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible...Where does PCSA stock trade?
Processa Pharmaceuticals Inc. (PCSA) is listed on NASDAQ.What sector and industry is PCSA in?
Processa Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PCSA?
Processa Pharmaceuticals Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $800.00 price target on 2024-04-25. Recent price targets range from $800.00 to $2000.00.What companies are similar to PCSA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare PCSA side-by-side with any of them on Quantisnow.How can I track PCSA on Quantisnow?
Quantisnow aggregates Processa Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCSA to receive live email and push alerts on every new disclosure.